120 results
Page 3 of 6
6-K
EX-99.1
a8apa 05zl
6 Jan 22
ObsEva Announces Positive Topline Results for Linzagolix 200 mg with Add-Back Therapy in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe Endometriosis-Associated Pain
6:30am
6-K
EX-99.1
mkk6n xdrvg
17 Dec 21
ObsEva Announces Positive CHMP Opinion for Linzagolix, an Oral GnRH Antagonist, for the Treatment of Uterine Fibroids
7:15am
6-K
EX-99.1
zg8nnht9ytr0y
13 Dec 21
ObsEva Appoints Will Brown as Chief Financial Officer
7:00am
6-K
EX-99.1
spmbc9u29dnc
10 Dec 21
ObsEva Hosts Symposium and Presents Clinical Data on Oral GnRH Antagonist Linzagolix at SEUD Congress 2021
8:12am
6-K
EX-99.2
d2b0x8hvgk906p
22 Nov 21
Obseva Announces U.S. FDA Acceptance of New Drug Application for Linzagolix
6:05am
6-K
EX-99.1
5chhz7h6p9gtrv6c
22 Nov 21
Obseva Announces U.S. FDA Acceptance of New Drug Application for Linzagolix
6:05am
6-K
EX-99.3
m9oga2x1
4 Nov 21
Index to Unaudited Condensed Consolidated Financial Statements
7:21am
6-K
EX-99.1
lkolnr7hzp6yg
29 Oct 21
ObsEva Announces Management Change
5:24pm
6-K/A
EX-99.2
hdvly953
13 Oct 21
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
5:24pm
6-K/A
EX-99.5
4pj3sd
13 Oct 21
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
5:24pm
6-K/A
EX-99.1
30hd78
13 Oct 21
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
5:24pm
6-K
hkowinc1o9
13 Oct 21
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
9:27am
6-K
EX-99.2
w4etu9g63
13 Oct 21
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
9:27am
6-K
EX-99.1
5y5ooer84u1 6fgihh
13 Oct 21
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
9:27am
6-K
EX-99.5
jtr0ohx
13 Oct 21
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
9:27am
6-K
EX-99.1
fg7qj6zv
27 Jul 21
Current report (foreign)
6:12am
6-K
EX-99.1
peh20jrs6 dtadbifdx
20 May 21
ObsEva Announces Final Results from the Phase 3 PRIMROSE Program of
6:30am
6-K
EX-99.1
qw5 opltg87
6 May 21
ObsEva appoints Clive Bertram as Chief Commercial Officer
6:05am
6-K
EX-99.3
au9sb 75bevmxy
6 May 21
Index to Unaudited Condensed Consolidated Financial Statements
6:03am
6-K
EX-1.1
1kfknvz6obu
5 Mar 21
Current report (foreign)
8:15am